1-20 of 42
J Crown
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract OT3-06-01: Phase Ib clinical trial of co PAN lisib in combination with T rastuzumab emtansine (T-DM1) in pre-treated unresectable locally advanced or metastatic HER 2-positive bre A st cancer (BC) “PANTHERA”-CTRIAL-IE 17-13

A Hassan, G Gullo, S O'Reilly, M Ruiz-Borrego, S Toomey, L Grogan, O Breathnach, PG Morris, JM Walshe, J Crown, D O'Mahony, A Falcon, K Egan, A Hernando, A Teiserskiene, CM Kelly, L Coate, BT Hennessy
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): OT3-06-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-OT3-06-01
Published: 15 February 2019
View article
Journal Articles

Abstract P3-06-13: Whole exome sequencing of HER2+ metastatic breast cancer (MBC) patients (pts) with extraordinary durable complete responses (ExdCR) to trastuzumab (T)

N Walsh, G Gullo, C Quinn, SJ Furney, J Crown
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P3-06-13.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P3-06-13
Published: 15 February 2019
View article
Journal Articles

Abstract P5-03-02: Pre-clinical investigation of PP2A inhibitor LB-100 in overcoming and preventing lapatinib resistance in HER2-positive breast cancer

N Conlon, M McDermott, B Browne, S Roche, F O'Neill, J Meiller, A Browne, A Eustace, DM Collins, N O'Donovan, J Crown
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P5-03-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P5-03-02
Published: 15 February 2019
View article
Journal Articles

Abstract PD3-11: HER2/ERBB2 status in “HER2 equivocal” breast cancers by FISH and ASCO-CAP guidelines: False-positives due to heterozygous deletions of alternative control loci

MF Press, JA Seoane, C Curtis, E Quinaux, R Guzman, G Sauter, W Eiermann, JR Mackey, N Robert, T Pienkowski, J Crown, M Martin, V Valero, V Bee, Y Ma, I Villalobos, DJ Slamon
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): PD3-11.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-PD3-11
Published: 15 February 2019
View article
Journal Articles

Abstract P4-07-08: Budesonide and loperamide do not impact the cytotoxicity of neratinib or HER2-directed monoclonal antibodies in HER2+ breast cancer cell lines

DM Collins, N Gaynor, N Conlon, G Gullo, AJ Eustace, J Crown
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P4-07-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P4-07-08
Published: 15 February 2019
View article
Journal Articles

Abstract P4-06-19: The effect of relieving adenosine-mediated immunosuppression on trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity (T-ADCC) against HER2+ breast cancer cell lines

N Gaynor, J Noone, J Monedero, EE Murphy, DJ O'Gorman, J Crown, DM Collins
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P4-06-19.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P4-06-19
Published: 15 February 2019
View article
Journal Articles

Abstract P6-21-01: Xentuzumab (BI 836845), an insulin-like growth factor (IGF)-neutralizing antibody (Ab), combined with exemestane and everolimus in hormone receptor-positive (HR+) locally advanced/metastatic breast cancer (LA/mBC): Randomized phase 2 results

J Crown, M-P Sablin, J Cortés, J Bergh, S-A Im, Y-S Lu, N Martínez, P Neven, KS Lee, S Morales, JA Pérez-Fidalgo, D Adamson, A Goncalves, A Prat, G Jerusalem, L Schlieker, R-M Espadero, T Bogenrieder, D Chin-Lun Huang, P Schmid
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-21-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P6-21-01
Published: 15 February 2019
View article
Journal Articles

Abstract P1-07-15: Withdrawn

C Desmedt, M Fornili, C Poncet, F Clatot, A Orenti, P Boracchi, A Di Leo, G Viale, E de Azambuja, C Sotiriou, J Crown, PA Francis, H Bonnefoi, M Piccart, E Biganzoli
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P1-07-15.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P1-07-15
Published: 15 February 2018
View article
Journal Articles

Abstract P4-03-15: Targeting Src kinase blocks development of afatinib resistance in HER2-positive breast cancer

N Conlon, A Canonici, C Morgan, M Cremona, BT Hennessey, A Eustace, N O'Brien, D Slamon, J Crown, N O'Donovan
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P4-03-15.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P4-03-15
Published: 15 February 2018
View article
Journal Articles

Abstract P6-08-17: Pregnancy associated breast cancer: Evaluating maternal outcomes. A multicentre study

L Prior, M Teo, M Greally, C Ward, C O'Leary, R Aslam, W Darwish, N Ahmed, G Watson, D Kelly, L Kiely, A Hassan, J Gleeson, H Featherstone, M Lim, H Murray, D Gallagher, J Westrup, B Hennessy, G Leonard, L Grogan, O Breathnach, A Horgan, L Coate, D O'Mahony, L Coate, S O'Reilly, R Gupta, M Keane, K Duffy, M O'Connor, J Kennedy, J McCaffrey, M Higgins, C Kelly, D Carney, G Gullo, J Crown, J Walshe
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P6-08-17.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P6-08-17
Published: 15 February 2018
View article
Journal Articles

Abstract P5-20-05: Impact of type of (neo)adjuvant systemic therapy (AdjTx) and total exposure to trastuzumab (TET) on long-term outcome of HER2-positive (HER2+) early stage breast cancer (ESBrCa)

G Gullo, N Walsh, D Fennelly, J Walshe, K O'Mahony, N Silva, J Ballot, G Calzaferri, C Quinn, D McDonnell, J Crown
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P5-20-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P5-20-05
Published: 15 February 2018
View article
Journal Articles

Abstract P5-11-03: Tumor CXCL16/CXCR6 expression and soluble CXCL16 in HER2+ breast cancer (BC)

DM Collins, SF Madden, AJ Eustace, S Toomey, EW Kay, J Fay, N O'Donovan, WM Gallagher, B Hennessy, J Crown
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P5-11-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P5-11-03
Published: 15 February 2018
View article
Journal Articles

Abstract OT3-06-05: A phase Ib/II trial of coPANlisib in combination with tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”

NM Keegan, J Walshe, G Gullo, J Kennedy, K Bulger, CM Kelly, J Crown, S Toomey, K Egan, J Kerr, M Given, A Hernando, A Teiserskiene, L Grogan, O Breathnach, PG Morris, M Keane, BT Hennessy
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): OT3-06-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-OT3-06-05
Published: 15 February 2018
View article
Journal Articles

Abstract P4-21-27: Plasma chemokine profile of HER2+ breast cancer (BC) patients treated with docetaxel (D) and carboplatin (C) in combination with trastuzumab (T) and/or lapatinib (L) in the neo-adjuvant setting

DM Collins, SF Madden, N Gaynor, WM Gallagher, N O'Donovan, J Crown
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P4-21-27.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-P4-21-27
Published: 15 February 2017
View article
Journal Articles

Abstract P1-05-18: Genomic copy number alterations (CNA) associated with pCR in HER2-positive (HER2+) early-stage breast cancer (BrCa) patients receiving neoadjuvant trastuzumab (T)

N Walsh, G Gullo, A Maguire, N O'Donovan, C Quinn, J Crown
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P1-05-18.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-P1-05-18
Published: 15 February 2017
View article
Journal Articles

Abstract P5-14-12: Long-term outcome of HER2-normal early stage breast cancer (ESBC) patients (Pts) treated with docetaxel-cyclophosphamide (TC) chemotherapy (CTx): Mature results of a single-institution experience

A Losurdo, G Gullo, C Buckley, C Lowry, J Ballot, N Silva, L Hammond, J Crown
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P5-14-12.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-P5-14-12
Published: 15 February 2017
View article
Journal Articles

Abstract P3-07-25: Improved clinical outcomes on enzalutamide observed in patients with PREDICT AR+ triple-negative breast cancer: prognosis or prediction?

K Miller, I Krop, L Schwartzberg, V Abramson, L Garcia-Estevez, J Eakle, R Nanda, D Yardley, F Ademuyiwa, S Chan, J Crown, M Danso, K Gelmon, L Ma, N Martinez-Janez, W Gradishar, J Steinberg, IC Tudor, H Uppal, VE Paton, J Parker, CA Hudis, TA Traina
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): P3-07-25.
DOI: https://doi.org/10.1158/1538-7445.SABCS15-P3-07-25
Published: 15 February 2016
View article
Journal Articles

Abstract P4-14-15: Pre-treatment stromal tumour-infiltrating lymphocytes (S-TILs) are correlated with complete response (CR) to chemotherapy (Chemo) plus trastuzumab (T) in HER2-positive (H+) metastatic breast cancer (MBC)

G Gullo, C Quinn, A Zacchia, D Fennelly, A Defrein, J Ballot, D Zanoni, J Walshe, M Maltese, E McDermott, J Crown
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): P4-14-15.
DOI: https://doi.org/10.1158/1538-7445.SABCS15-P4-14-15
Published: 15 February 2016
View article
Journal Articles

Abstract P6-03-09: Genetic polymorphism and correlation with treatment induced cardiotoxicity and prognosis in HER2 amplified early breast cancer patients

PF Peddi, SA Hurvitz, PA Fasching, L Wang, J Cunningham, RM Weinshilboum, D Liu, E Quinaux, H Fourmanoir, NJ Robert, V Valero, J Crown, C Falkson, A Brufsky, T Pienkowski, W Eiermann, M Martin, V Bee, DJ Slamon
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): P6-03-09.
DOI: https://doi.org/10.1158/1538-7445.SABCS15-P6-03-09
Published: 15 February 2016
View article
Journal Articles

Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer

DJ Slamon, W Eiermann, NJ Robert, J Giermek, M Martin, M Jasiowka, JR Mackey, A Chan, M-C Liu, T Pinter, V Valero, C Falkson, T Fornander, TA Shiftan, S Bensfia, S Hitier, N Xu, V Bée-Munteanu, P Drevot, MF Press, J Crown, On Behalf of the BCIRG-006 Investigators
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): S5-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS15-S5-04
Published: 15 February 2016
View article